Table 1 Univariate analysis for risk factors associated with reinfection of two-stage revision THAData are mean (range) or number (%) of episodes
From: The risk factors of failed reimplantation arthroplasty for periprosthetic hip infection
Variable | Success (N = 51) | Reinfection (N = 11) | HR (95% CI) | p value | |||
|---|---|---|---|---|---|---|---|
Age (years) | 57.8 | (27–86) | 53.2 | (42–79) | 0.97 (0.93–1.02) | 0.3621 | |
Male | 36 | (70%) | 7 | (63%) | 1.44 (0.42–4.93) | 0.5587 | |
Patient characteristics | BMI (kg/m2) | ||||||
<30 | 43 | (84%) | 5 | (46%) | – | ||
≥30 | 8 | (16%) | 6 | (54%) | 4.92 (1.50–16.1) | 0.0085* | |
Smoking | 17 | (33%) | 5 | (45%) | 1.55 (0.47–5.11) | 0.4641 | |
ASA | |||||||
2 | 28 | (55%) | 3 | (27%) | – | ||
3 | 23 | (45%) | 8 | (73%) | 2.97 (0.78–11.2) | 0.1077 | |
Diabetes mellitus | 8 | (16%) | 2 | (18%) | 1.24 (0.26–5.78) | 0.7764 | |
Hepatitis | 10 | (20%) | 4 | (36%) | 2.16 (0.63–7.40) | 0.2176 | |
Medical diseases | Gout | 6 | (12%) | 3 | (27%) | 2.27 (0.60–8.57) | 0.2257 |
CKD | 5 | (10%) | 1 | (9%) | 1.00 (0.12–7.86) | 0.9987 | |
ESRD | 1 | (2%) | 1 | (9%) | 3.96 (0.50–31.2) | 0.1910 | |
Drug abuse | 0 | (0%) | 2 | (18%) | 10.1 (2.11–48.0) | 0.0037* | |
Liver cirrhosis | 4 | (9%) | 6 | (54%) | 7.94 (2.39–26.2) | 0.0007* | |
Autoimmune disease | 3 | (6%) | 1 | (9%) | 1.81 (0.22–14.4) | 0.5579 | |
Staphylococcus aureus | 7 | (13.7%) | 2 | (18.1%) | 1.43 (0.31–6.67) | 0.6425 | |
Coagulase-negative Staphylococcus | 1 | (1.9%) | 1 | (9%) | 3.46 (0.43–27.7) | 0.2413 | |
Microbiology | Methicillin-resistant organism | 10 | (19.6%) | 1 | (9%) | 0.43 (0.05–3.40) | 0.4287 |
Gram-negative organism | 4 | (9%) | 4 | (36.3) | 4.83 (1.40–16.6) | 0.0124* | |
Polymicrobial organism | 4 | (9%) | 1 | (9%) | 1.57 (0.20–12.3) | 0.6651 | |
Culture-negative | 16 | (31.3%) | 2 | (18.1%) | 0.49 (0.10–2.28) | 0.3671 | |
Presence of sinus tract | 6 | (12%) | 7 | (63%) | 9.24 (2.66–32.0) | 0.0005* | |
Interim period less than 3 months | 9 | (17%) | 3 | (27%) | 1.78 (0.47–6.74) | 0.3949 | |
Operation-related factors | Repeated debridement between stage | 18 | (35%) | 10 | (91%) | 13.7 (1.75–107) | 0.0125* |
Perioperative Blood loss >1500 ml | 18 | (35%) | 5 | (45%) | 1.37 (0.41–4.49) | 0.6031 | |
Revision operative time >4 h | 26 | (51%) | 10 | (91%) | 8.47 (1.08–66.3) | 0.0419* | |
Allograft use in revision | 42 | (82%) | 9 | (82%) | 1.04 (0.22–4.83) | 0.9586 | |